Clearside Biomedical, Inc. Appoints Thomas Crawford as Vice President, Supply Chain
October 19, 2018 at 05:30 pm IST
Share
Clearside Biomedical, Inc. announced the appointment of Thomas Crawford, CSCP, as Vice President, Supply Chain. Mr. Crawford will be responsible for establishing and managing Clearside’s global supply chain for clinical testing, training and, if approved, trade distribution of suprachoroidal CLS-TA, the company’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space. In a career spanning more than 25 years, Mr. Crawford has extensive expertise in supply chain management, trade relations, product launches, and manufacturing operations. Before joining Clearside, he was Vice President of Supply Chain and Customer Service for Pharma Tech Industries, LLC.
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
CLEARSIDE BIOMEDICAL, INC. 
